国产重组链激酶溶栓治疗急性心肌梗塞的临床观察

A Clinical Observe on Thrombolysis with IntravenousRecombinant Streptokinase Made in China in Acute Myocardial Infarction

目的:观察国产重组链激酶(rSK)在急性心肌梗塞(AMI)静脉溶栓治疗的临床疗效和不良反应。方法:79例符合溶栓治疗的AMI患者,按用药情况分为rSK组30例和尿激酶(UK)组49例,观察冠状动脉再通率,出血并发症以及rSK的不良反应。结果:rSK组的临床血管再通率76.67%,显著高于UK组的55.10%(P<0.05)。两组出血并发症无显著性差异(P>0.05)。rSK组发生轻微过敏反应6.7%,低血压10.0%,对症治疗后迅速好转。结论:国产rSK溶栓治疗AMI,血管再通率高,不良反应发生率低,程度轻,为一安全有效的溶栓药物。

Objective:To Observe the clinical efficacy and adverse reaction of intravenous thrombolytic therapy using Recombinant Streptokinase(rSK) made in china in acute myocardical infarction(AMI).Methods:79 patients with Acute Myocardial Infaction.30 patients were treated with intravenous rSK and 49 patients were treated with UK.To abserve the patency of infarct-related coronary artery and reaction of rSK.Results:The patency of using rSK was 76.67%.It was higher than using UK(the rate was 55.10%)(P<0.05).The bleeding complication havn't obvious imparity between two groups(P>0.05).The rate of allergic reaction was 6.7%and hypotension was 10.0%ih using the rSK group.All recoverd after therapy.Conclusions:These data suggest rSK made in china is an effective and safe thrombolytic agent.